Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors

SIMPLE SUMMARY: Advanced neuroendocrine tumors originating in the intestinal tract and pancreas are treated with biologics that activate somatostatin receptors (lanreotide and octreotide), small molecule drugs that target the mTOR (everolimus) and VEGF and other signaling pathways (sunitinib), chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Chanjuan, Morse, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776394/
https://www.ncbi.nlm.nih.gov/pubmed/36551599
http://dx.doi.org/10.3390/cancers14246114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776394/
https://www.ncbi.nlm.nih.gov/pubmed/36551599
http://dx.doi.org/10.3390/cancers14246114

Ejemplares similares